The Secret of Lecanemab, Innovative Altzheimer Therapeutic.

Eisai announced that it will launch the anti-Aβ antibody Rekenbi in Japan on 20 December 2023. However, peak domestic sales of the innovative early-stage Alzheimer's disease treatment are mAodestly forecast at 98.6 billion yen. We analysed the circumstances behind this and the barriers to breaking the 100 billion yen mark.
https://miyata-bio.net/column/0000305/